Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Total Current Liabilities: 2022-2024

Historic Total Current Liabilities for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $39.5 million.

  • Entrada Therapeutics' Total Current Liabilities fell 65.98% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year decrease of 65.98%. This contributed to the annual value of $39.5 million for FY2024, which is 75.14% down from last year.
  • According to the latest figures from FY2024, Entrada Therapeutics' Total Current Liabilities is $39.5 million, which was down 75.14% from $158.8 million recorded in FY2023.
  • Entrada Therapeutics' Total Current Liabilities' 5-year high stood at $158.8 million during FY2023, with a 5-year trough of $22.0 million in FY2022.
  • Moreover, its 3-year median value for Total Current Liabilities was $39.5 million (2024), whereas its average is $73.4 million.
  • In the last 5 years, Entrada Therapeutics' Total Current Liabilities skyrocketed by 622.72% in 2023 and then tumbled by 75.14% in 2024.
  • Over the past 3 years, Entrada Therapeutics' Total Current Liabilities (Yearly) stood at $22.0 million in 2022, then surged by 622.72% to $158.8 million in 2023, then plummeted by 75.14% to $39.5 million in 2024.